

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/077086-2025>

Award

## **BH\_NonClinical\_Pharmacy\_Car-T**

Barts Health NHS Trust

UK5: Transparency notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2025/S 000-077086

Procurement identifier (OCID): ocds-h6vhtk-05e8d3

Published 26 November 2025, 9:46am

## **Scope**

## **Reference**

C402343

## **Description**

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.

The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products

At the time of writing it is only offered at 8 sites across the UK.

The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.

The price paid to the supplier will be capped at NICE / NHS England approved list prices.

## **Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products**

### **Supplier**

- Bristol Myers Squibb

### **Contract value**

- £2,100,000 excluding VAT
- £2,520,000 including VAT

Above the relevant threshold

### **Earliest date the contract will be signed**

8 December 2025

### **Contract dates (estimated)**

- 8 December 2025 to 5 December 2030
- Possible extension to 7 December 2035
- 10 years

Description of possible extension:

Option to extend contract by a further 5 years

## **Main procurement category**

Services

## **Options**

The right to additional purchases while the contract is valid.

Extension option

## **CPV classifications**

- 33000000 - Medical equipments, pharmaceuticals and personal care products
- 85149000 - Pharmacy services

---

## **Other information**

### **Conflicts assessment prepared/revised**

Yes

---

## **Procedure**

## Procedure type

Direct award

## Direct award justification

Single supplier - intellectual property or exclusive rights

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.

The products can only be supplied by the the proposed contractor, Bristol Myers Squibb.

---

## Supplier

### Bristol Myers Squibb

- Companies House: 02487574

Arc Uxbridge Sanderson Road, New Denham,

Denham

UB8 1DH

United Kingdom

Email: [jon.joyce@bms.com](mailto:jon.joyce@bms.com)

Region: UKJ13 - Buckinghamshire CC

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products

---

## Contracting authority

### **Barts Health NHS Trust**

- Public Procurement Organisation Number: PVTI-5832-LMDG

20 Churchill Place, Canary Wharf

London

E14 5HJ

United Kingdom

Email: [oliver.watling@nhs.net](mailto:oliver.watling@nhs.net)

Website: <https://www.bartshealth.nhs.uk>

Region: UKI42 - Tower Hamlets

Organisation type: Public authority - central government